Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS

Inclusion Criteria: * Male or female, aged between 18 and 75 years (inclusive). * Diagnosis of sepsis. * Diagnosis of Acute Respiratory Distress Syndrome (ARDS) suspected or confirmed to be caused by sepsis. * Time from ARDS diagnosis to signing the informed consent form (ICF) does not exceed 48 hours. * The subject (or their legally authorized representative) has fully understood the study's purpose, nature, procedures, and potential adverse events, voluntarily agrees to participate, and provides written informed consent. Exclusion Criteria: * Known allergy or hypersensitivity to the active ingredient or any excipients of the investigational product; or a history of allergic disorders. * Expected survival time is less than 48 hours at the time of screening. * Sepsis with extensive burns as the primary cause. * Currently diagnosed with active malignancy; or malignancy with distant metastasis; or cancer patients with cachexia; or patients with severe organ dysfunction or visceral hemorrhage due to tumor obstruction, space-occupying effect, or compression, for whom surgical intervention is difficult or has not yet been performed. * Currently receiving or requiring Extracorporeal Membrane Oxygenation (ECMO) therapy. * Presence of chronic severe organ failure or immunodeficiency/immunosuppression. * Thrombocytopenia at screening, active/uncontrolled bleeding, or patients whom the investigator considers to have a current or prior high risk of bleeding. * Diagnosis of neutropenia. * Positive for Hepatitis B surface antigen (HBsAg) with HBV-DNA \> 1000 copies/mL or 200 IU/mL; positive for Hepatitis C virus antibody (HCV-Ab); positive for Human Immunodeficiency Virus antibody (HIV-Ab); or positive for Treponema pallidum antibody. * Participation in other drug or medical device clinical trials within 3 months prior to this study, or current participation in another clinical trial. * Pregnant or breastfeeding women, or women planning to become pregnant within the next 6 months. * Patients whose underlying primary disease cannot be effectively treated. * Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this study.